Tailored Preclinical Solutions for Nucleic Acid Therapies
- Non-GLP preclinicalpre-clinical to IND-enabling
- In vitro & in vivo pharmacology & toxicology
- Customized protocol
- Surgery, specialized administration and dosing routes
- DART
- Specialty models and endpoints
- Pathology
- Immunohistochemistry (IHC)
- Single combination non-GLP pharmacology and GLP toxicology studies
- Analytical support
- Method development, validation, and sample analysis (early screening through preclinical & clinical)
- Bioanalysis/PK: infiltration/engraftment, persistence & shedding
- Biomarkers: assay development & testing
- BioCMC testing & analytical control strategy– safety, identity, strength & purity
